COMMUNIQUÉS West-GlobeNewswire

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
11/06/2026
PMA supplement under FDA review with potential approval in H2 2026, potentially expanding the Company’s addressable market to include TCAR in addition to CAS carotid stenting procedures MIAMI, June 11, 2026 (GLOBE [...]
European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences’ Patent Portfolio to More Than 45 Granted Patents
11/06/2026
Patent covers machine-learning models that use ECG data to estimate echocardiogram parameters indicative of diastolic function Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“ [...]
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
11/06/2026
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free [...]
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
11/06/2026
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab – – [...]
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
11/06/2026
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall [...]
Tris Pharma to Present on Dual NOP/MOP Receptor Agonist in Pain Management and Substance Use Disorder at the College on Problems of Drug Dependence (CPDD) 88th Annual Scientific Meeting, 2026
11/06/2026
Cebranopadol is an investigational, first-in-class dual-NMR agonist in development for acute and chronic pain as well as opioid use disorder Five scientific presentations will feature preclinical and clinical data [...]
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
11/06/2026
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Teverelix® as a potential long-acting precision medicine therapy for women [...]
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
11/06/2026
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists [...]
Spinach® is the Number One Vape Brand in Canada
11/06/2026
Spinach® vapes, known for exceptional quality, bold flavor profiles and advanced hardware, continue to resonate with adult consumers across Canada TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: [...]
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
11/06/2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive [...]
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
11/06/2026
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026) [...]
What Science-Backed Subscription Health Programs Measure Differently
11/06/2026
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the [...]
Clinical Data Showed Average 67% Pain Score Reduction and 50% Gain in Walking Distance with Cartigenix HP® in 90 Days*†
11/06/2026
A randomized, placebo-controlled study published in Pharmaceutical Research documented a 64% reduction in WOMAC pain scores and measurable cartilage regeneration biomarkers at 90 days, a first for the joint health [...]
BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
11/06/2026
BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with favorable pharmacokinetic properties SAN [...]
Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com
11/06/2026
My Grief Angels Inc. launches a first-of-its-kind Father’s Day grief support initiative — a complete, free bundle of resources assembled by bereaved mothers, for bereaved fathers. New York, NY, June 11, 2026 (GLOBE [...]
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
11/06/2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess [...]
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
11/06/2026
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14 [...]
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
11/06/2026
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 [...]
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline
11/06/2026
Financing follows a series of major milestones for Neion Bio, including the company’s emergence from stealth, execution of its first commercial agreement, and continued expansion and advancement of its development [...]

Pages